Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib as Front-Line Therapy in Advanced Soft Tissue Sarcoma
NCT02300545Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in soft tissue sarcoma (STS), sponsored by Washington University School of Medicine. Primary endpoint: Clinical Benefit Rate at 16 weeks. Started Apr 2015; status: completed.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02300545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300545.